Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AFT PharmaceuticalsASX:AFP 90 Cyclically Adjusted Price-to-FCF is 343.00 as of Sep. 15, 2026. GuruFocus rates ASX:AFP with a GF Score™ of 90/100 and a GF Value™ of A$3.52 (Fairly Valued). The stock has 2 warning signs investors should review. Among 328 Drug Manufacturers companies, AFT Pharmaceuticals ranks worse than 304877.74% on this metric.
The historical rank and industry rank for AFT Pharmaceuticals's Cyclically Adjusted Price-to-FCF or its related term are showing as below:
ASX:AFP's Cyclically Adjusted Price-to-FCF is not ranked *
in the Drug Manufacturers industry.
Industry Median: 27.505 * Ranked among companies with meaningful Cyclically Adjusted Price-to-FCF only.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.
AFT Pharmaceuticals's adjusted free cash flow per share data of for the fiscal year that ended in Mar26 was A$-0.101. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is A$0.01 for the trailing ten years ended in Mar26.
Shiller PE for Stocks: The True Measure of Stock Valuation
Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.
AFT Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms
AFT Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data
* Premium members only.
The historical data trend for AFT Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:AFP vs ZTS, UTHR, VTRS: Cyclically Adjusted Price-to-FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AFT Pharmaceuticals Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where AFT Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.
AFT Pharmaceuticals's Cyclically Adjusted Price-to-FCF for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted Price-to-FCF of 343.00 mean?
AFT Pharmaceuticals (ASX:AFP) has a Cyclically Adjusted Price-to-FCF of 343.00 as of Sep. 15, 2026. Cyclically Adjusted Price-to-FCF Ratio is the ratio of share price to a company's inflation-adjusted FCF per share over a 10-year period. View historical data on AFT Pharmaceuticals and its competitors. According to the industry distribution chart, AFT Pharmaceuticals ranks #999999 out of 328 companies in the Drug Manufacturers industry.
Is AFT Pharmaceuticals' Cyclically Adjusted Price-to-FCF too high?
AFT Pharmaceuticals' current Cyclically Adjusted Price-to-FCF is 343.00. The Drug Manufacturers industry median Cyclically Adjusted Price-to-FCF is 27.51. AFT Pharmaceuticals' value of 343.00 is 1147% above this industry median. Based on the distribution chart, AFT Pharmaceuticals ranks #999999 out of 328 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, AFT Pharmaceuticals has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AFT Pharmaceuticals' Cyclically Adjusted Price-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AFT Pharmaceuticals ranks #999999 out of 328 companies for Cyclically Adjusted Price-to-FCF. This places AFT Pharmaceuticals in the lower half of its industry. The industry median Cyclically Adjusted Price-to-FCF is 27.51. AFT Pharmaceuticals' value of 343.00 is 1147% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Price-to-FCF for a Drug Manufacturers company?
The median Cyclically Adjusted Price-to-FCF among Drug Manufacturers companies is 27.51, based on 328 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted Price-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted Price-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AFT Pharmaceuticals's current Cyclically Adjusted Price-to-FCF of 343.00 is 1147% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Price-to-FCF mean?
A high Cyclically Adjusted Price-to-FCF can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted Price-to-FCF Ratio is the ratio of share price to a company's inflation-adjusted FCF per share over a 10-year period. View historical data on AFT Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Cyclically Adjusted Price-to-FCF is 27.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AFT Pharmaceuticals's current Cyclically Adjusted Price-to-FCF is 343.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AFT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, AFT Pharmaceuticals (ASX:AFP) is currently considered Fairly Valued. The stock's GF Value™ is A$3.52, compared to a current price of A$3.43 — trading 2.6% below its estimated fair value. The current Cyclically Adjusted Price-to-FCF is 343.00 and 1147% above the Drug Manufacturers industry median of 27.51. AFT Pharmaceuticals' overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Price-to-FCF calculated?
Cyclically Adjusted Price-to-FCF is calculated from a company's financial statements. For AFT Pharmaceuticals (ASX:AFP), the current Cyclically Adjusted Price-to-FCF is 343.00 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AFT Pharmaceuticals (ASX:AFP) Overvalued in 2026?
Based on GuruFocus' analysis, AFT Pharmaceuticals stock appears to be undervalued.
The current stock price of A$3.43 is trading 2.6% below its estimated GF Value™ of A$3.52.
GuruFocus considers AFT Pharmaceuticals to be Fairly Valued.
Key valuation signals for ASX:AFP:
Cyclically Adjusted Price-to-FCF: 343.00
GF Value™: A$3.52 vs. price of A$3.43 (2.6% below fair value)
Industry Position: 1147% above the Drug Manufacturers median (#999999 of 328)
No single metric tells the full story. See the ASX:AFP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
90GF Score
Get the complete analysis for ASX:AFP
Cyclically Adjusted Price-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AFP has been successfully added to your 
